Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.04
NYSE:MD's Cash to Debt is ranked lower than
88% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. NYSE:MD: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MD' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.33 Max: 312.43
Current: 0.04
0.01
312.43
Equity to Asset 0.50
NYSE:MD's Equity to Asset is ranked higher than
52% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. NYSE:MD: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MD' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.76 Max: 0.88
Current: 0.5
0.5
0.88
Interest Coverage 10.50
NYSE:MD's Interest Coverage is ranked higher than
56% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 7.76 vs. NYSE:MD: 10.50 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MD' s Interest Coverage Range Over the Past 10 Years
Min: 10.5  Med: 97.83 Max: 294.93
Current: 10.5
10.5
294.93
F-Score: 4
Z-Score: 2.80
M-Score: -2.41
WACC vs ROIC
3.05%
9.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.74
NYSE:MD's Operating margin (%) is ranked higher than
86% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 6.84 vs. NYSE:MD: 18.74 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MD' s Operating margin (%) Range Over the Past 10 Years
Min: 18.74  Med: 22.36 Max: 24.16
Current: 18.74
18.74
24.16
Net-margin (%) 10.97
NYSE:MD's Net-margin (%) is ranked higher than
73% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. NYSE:MD: 10.97 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MD' s Net-margin (%) Range Over the Past 10 Years
Min: 10.97  Med: 13.69 Max: 15.84
Current: 10.97
10.97
15.84
ROE (%) 13.63
NYSE:MD's ROE (%) is ranked higher than
66% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 9.67 vs. NYSE:MD: 13.63 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MD' s ROE (%) Range Over the Past 10 Years
Min: 12.79  Med: 14.84 Max: 17.59
Current: 13.63
12.79
17.59
ROA (%) 7.12
NYSE:MD's ROA (%) is ranked higher than
67% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. NYSE:MD: 7.12 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MD' s ROA (%) Range Over the Past 10 Years
Min: 7.12  Med: 10.5 Max: 12.23
Current: 7.12
7.12
12.23
ROC (Joel Greenblatt) (%) 270.73
NYSE:MD's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 18.74 vs. NYSE:MD: 270.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 270.73  Med: 693.2 Max: 755.09
Current: 270.73
270.73
755.09
Revenue Growth (3Y)(%) 17.40
NYSE:MD's Revenue Growth (3Y)(%) is ranked higher than
83% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. NYSE:MD: 17.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:MD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.9  Med: 14.5 Max: 37.1
Current: 17.4
6.9
37.1
EBITDA Growth (3Y)(%) 16.20
NYSE:MD's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 7.40 vs. NYSE:MD: 16.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:MD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.4  Med: 12.9 Max: 34.6
Current: 16.2
-1.4
34.6
EPS Growth (3Y)(%) 13.90
NYSE:MD's EPS Growth (3Y)(%) is ranked higher than
65% of the 133 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. NYSE:MD: 13.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:MD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.2  Med: 13.3 Max: 71.5
Current: 13.9
-20.2
71.5
» NYSE:MD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MD Guru Trades in Q4 2015

Joel Greenblatt 265,744 sh (+959.75%)
Jeremy Grantham 71,700 sh (+54.86%)
Pioneer Investments 240,192 sh (+39.33%)
Vanguard Health Care Fund 805,600 sh (unchged)
Ray Dalio Sold Out
John Hussman Sold Out
Mariko Gordon 48,544 sh (-1.21%)
Paul Tudor Jones 4,400 sh (-48.84%)
Chuck Royce 11,662 sh (-86.86%)
» More
Q1 2016

MD Guru Trades in Q1 2016

Ray Dalio 7,732 sh (New)
Columbia Wanger 1,041,677 sh (New)
Jim Simons 441,600 sh (New)
Joel Greenblatt 351,118 sh (+32.13%)
Pioneer Investments 262,512 sh (+9.29%)
Mariko Gordon 52,787 sh (+8.74%)
Vanguard Health Care Fund 805,600 sh (unchged)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
Jeremy Grantham 71,400 sh (-0.42%)
» More
Q2 2016

MD Guru Trades in Q2 2016

Pioneer Investments 315,383 sh (+20.14%)
Vanguard Health Care Fund 805,600 sh (unchged)
Jeremy Grantham Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Columbia Wanger 972,106 sh (-6.68%)
Mariko Gordon 43,087 sh (-18.38%)
Jim Simons 252,200 sh (-42.89%)
» More
Q3 2016

MD Guru Trades in Q3 2016

First Pacific Advisors 23,570 sh (New)
Vanguard Health Care Fund 805,600 sh (unchged)
Jim Simons Sold Out
Mariko Gordon Sold Out
Columbia Wanger 847,522 sh (-12.82%)
Pioneer Investments 134,446 sh (-57.37%)
» More
» Details

Insider Trades

Latest Guru Trades with MD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:OTCPK:SKHCY, NAS:WOOF, NYSE:HLS, NAS:AMSG, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, OTCPK:RMSYF, NAS:SCAI, NYSE:SEM, NYSE:THC, NYSE:AMN, NAS:AMED, NAS:PAHC, NAS:HWAY, NAS:LHCG, NAS:SGRY, NYSE:USPH, NYSE:CYH » details
Traded in other countries:PDC.Germany, MD.Mexico,
Mednax Inc is a provider of physician services including newborn, maternal-fetal, pediatric subspecialties, and anesthesia care.

Mednax Inc was incorporated in Florida in 2007 and is the successor to Pediatrix Medical Group, Inc., which was incorporated in Florida in 1979. The Company is a provider of physician services including Neonatal Care, Maternal-fetal Care, Pediatric Cardiology Care, Other Pediatric Subspecialty Care and Anesthesia Care. The Company's national network comprised over 3,240 affiliated physicians, including over 1,100 physicians who provide neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units ("NICUs"), to babies born prematurely or with medical complications. The Company over 1,150 affiliated physicians who provide anesthesia care to patients in connection with surgical and other procedures, as well as pain management. In addition, it has over 255 affiliated physicians who provide maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. The Company's network includes other pediatric subspecialists, including approximately 145 physicians providing pediatric intensive care, 120 physicians providing pediatric cardiology care, 100 physicians providing hospital-based pediatric care and 20 physicians providing pediatric surgical care. The Company provides clinical care to babies born prematurely or with complications within specific units at hospitals, mainly NICUs, through a team of experienced neonatal physician subspecialists called neonatologists, neonatal nurse practitioners and other pediatric clinicians. The Company provides outpatient and inpatient clinical care to expectant mothers and their unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, such as maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers and genetic counselors. It provides inpatient and outpatient pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease as well as adults with congenital heart defects through its affiliated pediatric cardiologist subspecialists and other clinicians such as pediatric nurse practitioners, echocardiographers and other diagnostic technicians, and exercise physiologists. Its network includes pediatric intensivists, who are hospital-based pediatricians with additional education and training in caring for critically ill or injured children and adolescents, and pediatric hospitalists, who are hospital-based pediatricians specializing in inpatient care and management of acutely ill children. The Company provides anesthesia care through a team of experienced physician anesthesiologists, certified registered nurse anesthetists and anesthesia assistants. It has physicians who provide maternal-fetal medical care to expectant mothers experiencing complicated pregnancies and obstetricians hospitalize services

Ratios

vs
industry
vs
history
P/E(ttm) 18.18
MD's P/E(ttm) is ranked higher than
69% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 25.07 vs. MD: 18.18 )
Ranked among companies with meaningful P/E(ttm) only.
MD' s P/E(ttm) Range Over the Past 10 Years
Min: 6.95  Med: 18.12 Max: 26.73
Current: 18.18
6.95
26.73
Forward P/E 14.64
MD's Forward P/E is ranked higher than
62% of the 53 Companies
in the Global Medical Care industry.

( Industry Median: 16.18 vs. MD: 14.64 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.18
MD's PE(NRI) is ranked higher than
72% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 25.14 vs. MD: 18.18 )
Ranked among companies with meaningful PE(NRI) only.
MD' s PE(NRI) Range Over the Past 10 Years
Min: 8.01  Med: 18.24 Max: 27.01
Current: 18.18
8.01
27.01
Price/Owner Earnings (ttm) 17.08
MD's Price/Owner Earnings (ttm) is ranked higher than
74% of the 88 Companies
in the Global Medical Care industry.

( Industry Median: 25.79 vs. MD: 17.08 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MD' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.51  Med: 15.95 Max: 23.37
Current: 17.08
5.51
23.37
P/B 2.33
MD's P/B is ranked higher than
52% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 2.39 vs. MD: 2.33 )
Ranked among companies with meaningful P/B only.
MD' s P/B Range Over the Past 10 Years
Min: 1.23  Med: 2.35 Max: 3.59
Current: 2.33
1.23
3.59
P/S 1.99
MD's P/S is ranked lower than
63% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.45 vs. MD: 1.99 )
Ranked among companies with meaningful P/S only.
MD' s P/S Range Over the Past 10 Years
Min: 1.13  Med: 2.36 Max: 3.83
Current: 1.99
1.13
3.83
PFCF 16.25
MD's PFCF is ranked higher than
72% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. MD: 16.25 )
Ranked among companies with meaningful PFCF only.
MD' s PFCF Range Over the Past 10 Years
Min: 6.38  Med: 14.6 Max: 20.76
Current: 16.25
6.38
20.76
POCF 14.85
MD's POCF is ranked lower than
52% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 14.12 vs. MD: 14.85 )
Ranked among companies with meaningful POCF only.
MD' s POCF Range Over the Past 10 Years
Min: 5.86  Med: 13.7 Max: 19.7
Current: 14.85
5.86
19.7
EV-to-EBIT 13.57
MD's EV-to-EBIT is ranked higher than
72% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 19.66 vs. MD: 13.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MD' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 11.8 Max: 16.9
Current: 13.57
5.2
16.9
EV-to-EBITDA 11.89
MD's EV-to-EBITDA is ranked higher than
64% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. MD: 11.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
MD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 11 Max: 15.6
Current: 11.89
5
15.6
PEG 1.34
MD's PEG is ranked higher than
78% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 2.64 vs. MD: 1.34 )
Ranked among companies with meaningful PEG only.
MD' s PEG Range Over the Past 10 Years
Min: 0.62  Med: 1.3 Max: 2.09
Current: 1.34
0.62
2.09
Shiller P/E 25.62
MD's Shiller P/E is ranked higher than
58% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 27.06 vs. MD: 25.62 )
Ranked among companies with meaningful Shiller P/E only.
MD' s Shiller P/E Range Over the Past 10 Years
Min: 13.06  Med: 26.32 Max: 42.09
Current: 25.62
13.06
42.09
Current Ratio 1.39
MD's Current Ratio is ranked higher than
56% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. MD: 1.39 )
Ranked among companies with meaningful Current Ratio only.
MD' s Current Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.37 Max: 5.12
Current: 1.39
0.77
5.12
Quick Ratio 1.39
MD's Quick Ratio is ranked higher than
59% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. MD: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
MD' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.37 Max: 5.12
Current: 1.39
0.77
5.12
Days Sales Outstanding 57.44
MD's Days Sales Outstanding is ranked lower than
70% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. MD: 57.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
MD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.59  Med: 52.83 Max: 58.39
Current: 57.44
46.59
58.39
Days Payable 4.11
MD's Days Payable is ranked lower than
93% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 38.65 vs. MD: 4.11 )
Ranked among companies with meaningful Days Payable only.
MD' s Days Payable Range Over the Past 10 Years
Min: 3.59  Med: 4.36 Max: 7.33
Current: 4.11
3.59
7.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
MD's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. MD: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.5  Med: -1.6 Max: 3.4
Current: 2.1
-17.5
3.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.86
MD's Price/Projected FCF is ranked higher than
82% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 1.64 vs. MD: 0.86 )
Ranked among companies with meaningful Price/Projected FCF only.
MD' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.46  Med: 1.02 Max: 3.76
Current: 0.86
0.46
3.76
Price/DCF (Earnings Based) 0.99
MD's Price/DCF (Earnings Based) is ranked higher than
84% of the 31 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. MD: 0.99 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.85
MD's Price/Median PS Value is ranked higher than
70% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 1.00 vs. MD: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
MD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.98 Max: 2.16
Current: 0.85
0.21
2.16
Price/Peter Lynch Fair Value 1.26
MD's Price/Peter Lynch Fair Value is ranked higher than
76% of the 42 Companies
in the Global Medical Care industry.

( Industry Median: 2.54 vs. MD: 1.26 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MD' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.09  Med: 1.32 Max: 4.27
Current: 1.26
0.09
4.27
Earnings Yield (Greenblatt) (%) 7.35
MD's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. MD: 7.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.9  Med: 8.4 Max: 19.1
Current: 7.35
5.9
19.1
Forward Rate of Return (Yacktman) (%) 20.10
MD's Forward Rate of Return (Yacktman) (%) is ranked higher than
75% of the 113 Companies
in the Global Medical Care industry.

( Industry Median: 10.28 vs. MD: 20.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 14.8  Med: 19.4 Max: 28
Current: 20.1
14.8
28

More Statistics

Revenue (TTM) (Mil) $3,094
EPS (TTM) $ 3.65
Beta0.12
Short Percentage of Float9.83%
52-Week Range $59.36 - 76.96
Shares Outstanding (Mil)93.64

Analyst Estimate

Dec16 Dec17
Revenue (Mil $)
EPS ($) 4.14 4.58
EPS w/o NRI ($) 4.14 4.58
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:MD

Headlines

Articles On GuruFocus.com
5 Positions With Great Returns in 2015 Jan 03 2016 
Weekly CEO Sells Highlight Sep 06 2015 
MEDNAX Inc. -- Only 10% Growth Last Week?! Nov 02 2014 
Groups of Gurus Hold 10-Year Low P/B Stocks - ATVI, CHL, MD Dec 20 2013 
5 Inexpensive Stocks for Your Portfolio Jan 19 2012 
Mednax, a Quality Healthcare Stock to Consider Oct 18 2011 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 7,456 Shares Dec 10 2010 
MEDNAX, INC. (MD) COO / Pediatrix Division David A. Clark sells 2,960 Shares Dec 03 2010 
MEDNAX, INC. (MD) CFO Vivian Lopez-blanco sells 1,850 Shares Nov 05 2010 
MEDNAX, INC. Reports Operating Results (10-Q) Nov 03 2010 

More From Other Websites
ETFs with exposure to MEDNAX, Inc. : December 2, 2016 Dec 02 2016
MEDNAX, Inc. breached its 50 day moving average in a Bullish Manner : MD-US : November 22, 2016 Nov 22 2016
MEDNAX to Present at Upcoming Investor Conferences Nov 22 2016
MEDNAX to Present at Upcoming Investor Conferences Nov 22 2016
Hackers target ATMs across Europe as cyber threat grows Nov 21 2016
Hackers target ATMs across Europe as cyber threat grows Nov 21 2016
Hackers target European ATMs in spree that highlights new cyber threat Nov 21 2016
Hackers target European ATMs in spree that highlights new cyber threat Nov 21 2016
MEDNAX downgraded by Mizuho Nov 09 2016
MEDNAX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Nov 07 2016
MEDNAX Announces Divisional Leadership Changes Nov 07 2016
MEDNAX Leadership to Present at Becker’s Hospital Review 5th Annual CEO + CFO Roundtable Nov 04 2016
MEDNAX Leadership to Present at Becker’s Hospital Review 5th Annual CEO + CFO Roundtable Nov 04 2016
MEDNAX, INC. Financials Nov 02 2016
How to Invest in Your Favorite MD Nov 02 2016
MEDNAX to Present at Upcoming Investor Conferences Nov 02 2016
MEDNAX to Present at Upcoming Investor Conferences Nov 02 2016
Mednax Remains Unlikely Target as Medical Mergers Gain Steam Nov 01 2016
ETF’s with exposure to MEDNAX, Inc. : October 31, 2016 Oct 31 2016
MEDNAX, Inc. :MD-US: Earnings Analysis: Q3, 2016 By the Numbers : October 28, 2016 Oct 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)